141 related articles for article (PubMed ID: 38780312)
21. Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation.
Franko A; Merkel D; Kovarova M; Hoene M; Jaghutriz BA; Heni M; Königsrainer A; Papan C; Lehr S; Häring HU; Peter A
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227635
[TBL] [Abstract][Full Text] [Related]
22. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.
Viganò M; Valenti L; Lampertico P; Facchetti F; Motta BM; D'Ambrosio R; Romagnoli S; Dongiovanni P; Donati B; Fargion S; Colombo M
Hepatology; 2013 Oct; 58(4):1245-52. PubMed ID: 23564580
[TBL] [Abstract][Full Text] [Related]
23. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.
Hernaez R; McLean J; Lazo M; Brancati FL; Hirschhorn JN; Borecki IB; Harris TB; ; Nguyen T; Kamel IR; Bonekamp S; Eberhardt MS; Clark JM; Kao WH; Speliotes EK
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1183-1190.e2. PubMed ID: 23416328
[TBL] [Abstract][Full Text] [Related]
24. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.
Manchiero C; Nunes AKDS; Magri MC; Dantas BP; Mazza CC; Barone AA; Tengan FM
BMC Infect Dis; 2017 Dec; 17(1):780. PubMed ID: 29258449
[TBL] [Abstract][Full Text] [Related]
25. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
Zampino R; Coppola N; Cirillo G; Boemio A; Pisaturo M; Marrone A; Macera M; Sagnelli E; Perrone L; Adinolfi LE; Miraglia del Giudice E
J Viral Hepat; 2013 Aug; 20(8):517-23. PubMed ID: 23808989
[TBL] [Abstract][Full Text] [Related]
26. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
Nat Med; 2023 Oct; 29(10):2643-2655. PubMed ID: 37749332
[TBL] [Abstract][Full Text] [Related]
27. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
[TBL] [Abstract][Full Text] [Related]
28. Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.
De Nicola S; Dongiovanni P; Aghemo A; Cheroni C; D'Ambrosio R; Pedrazzini M; Marabita F; Donnici L; Maggioni M; Fargion S; Colombo M; De Francesco R; Valenti L
PLoS One; 2014; 9(8):e106022. PubMed ID: 25171251
[TBL] [Abstract][Full Text] [Related]
29. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
[TBL] [Abstract][Full Text] [Related]
30. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.
Luukkonen PK; Qadri S; Lehtimäki TE; Juuti A; Sammalkorpi H; Penttilä AK; Hakkarainen A; Orho-Melander M; Arola J; Yki-Järvinen H
J Clin Endocrinol Metab; 2021 Jan; 106(1):e300-e315. PubMed ID: 33064150
[TBL] [Abstract][Full Text] [Related]
31. Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries.
Rutledge SM; Soper ER; Ma N; Pejaver V; Friedman SL; Branch AD; Kenny EE; Belbin GM; Abul-Husn NS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2578-2587.e11. PubMed ID: 36610497
[TBL] [Abstract][Full Text] [Related]
32. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
33. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
[TBL] [Abstract][Full Text] [Related]
34. PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease.
Valenti L; Dongiovanni P; Ginanni Corradini S; Burza MA; Romeo S
Dig Liver Dis; 2013 Aug; 45(8):619-24. PubMed ID: 23333103
[TBL] [Abstract][Full Text] [Related]
35. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
[TBL] [Abstract][Full Text] [Related]
36. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
Valenti L; Al-Serri A; Daly AK; Galmozzi E; Rametta R; Dongiovanni P; Nobili V; Mozzi E; Roviaro G; Vanni E; Bugianesi E; Maggioni M; Fracanzani AL; Fargion S; Day CP
Hepatology; 2010 Apr; 51(4):1209-17. PubMed ID: 20373368
[TBL] [Abstract][Full Text] [Related]
37. The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients.
Brouwer WP; van der Meer AJ; Boonstra A; Pas SD; de Knegt RJ; de Man RA; Hansen BE; ten Kate FJ; Janssen HL
Liver Int; 2015 Feb; 35(2):438-47. PubMed ID: 25284145
[TBL] [Abstract][Full Text] [Related]
38. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study.
Wagenknecht LE; Palmer ND; Bowden DW; Rotter JI; Norris JM; Ziegler J; Chen YD; Haffner S; Scherzinger A; Langefeld CD
Liver Int; 2011 Mar; 31(3):412-6. PubMed ID: 21281435
[TBL] [Abstract][Full Text] [Related]
39. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.
Valenti L; Rumi M; Galmozzi E; Aghemo A; Del Menico B; De Nicola S; Dongiovanni P; Maggioni M; Fracanzani AL; Rametta R; Colombo M; Fargion S
Hepatology; 2011 Mar; 53(3):791-9. PubMed ID: 21319195
[TBL] [Abstract][Full Text] [Related]
40. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.
Kabbani M; Michailidis E; Steensels S; Fulmer CG; Luna JM; Le Pen J; Tardelli M; Razooky B; Ricardo-Lax I; Zou C; Zeck B; Stenzel AF; Quirk C; Foquet L; Ashbrook AW; Schneider WM; Belkaya S; Lalazar G; Liang Y; Pittman M; Devisscher L; Suemizu H; Theise ND; Chiriboga L; Cohen DE; Copenhaver R; Grompe M; Meuleman P; Ersoy BA; Rice CM; de Jong YP
Cell Rep; 2022 Sep; 40(11):111321. PubMed ID: 36103835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
